Managing smaller but flexible automation: back to the future
2003

Flexible Automation in Drug Discovery

publication Evidence: moderate

Author Information

Author(s): Derek J. Hook, David M. Evans, Mark Deiparine, Joseph Russo, Christopher Drabik

Primary Institution: Psychiatric Genomics, Inc.

Hypothesis

Can flexible automation improve drug discovery processes?

Conclusion

The study suggests that a multiparametric approach to drug discovery may yield more effective and novel therapies for psychiatric diseases.

Supporting Evidence

  • The automation approach allows for high-throughput screening of complex diseases.
  • Using gene expression assays can provide insights into the effectiveness of compounds.
  • The study emphasizes the need for a systems biology approach in drug discovery.

Takeaway

This study shows that using flexible automation can help find new medicines faster and better, especially for complex diseases like mental illness.

Methodology

The study utilized a Multi-Parameter High Throughput Screen (MPHTSSM) to measure gene expression levels in response to test compounds.

Limitations

The complexity of the assay and the high cost per assay plate may limit its widespread application.

Digital Object Identifier (DOI)

10.1080/1463924032000121165

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication